Overview
An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Status:
Enrolling by invitation
Enrolling by invitation
Trial end date:
2025-03-01
2025-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
TG Therapeutics, Inc.
Criteria
Inclusion Criteria:- Prior treatment in clinical trial UTX-TGR-304
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria:
- Patients refractory to ublituximab + TGR-1202
- Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's
transformation)